Literature DB >> 2922762

Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites.

B G Lake1, T J Gray, J G Evans, D F Lewis, J A Beamand, K L Hue.   

Abstract

Single doses of coumarin (125 mg/kg, ip) produced a depletion of hepatic nonprotein sulfhydryl groups (mainly reduced glutathione; GSH) in young male Sprague-Dawley rats after 2 hr and increased liver weight and produced hepatic centrilobular necrosis after 24 hr. Coumarin also produced time- and dose-dependent toxic effects in primary rat hepatocyte cultures. A marked reduction of GSH levels was also observed in vitro and this was not due either to the formation of oxidized glutathione (GSSG) or to the leakage of GSH and/or GSSG from the hepatocytes. Coumarin-induced toxicity in rat hepatocytes could be inhibited by the cytochrome P450 inhibitors ellipticine and metyrapone and potentiated by depleting hepatocyte GSH levels with diethyl maleate. In contrast to coumarin, dihydrocoumarin--which lacks the 3,4-double bond--produced little toxicity in rat hepatocytes either in vivo (127 and 254 mg/kg, ip) or in vitro. Similarly, coumarin was more toxic to rat hepatocytes than a number of known coumarin metabolites including 3- and 7-hydroxycoumarin and o-hydroxyphenylacetic acid. The results of these studies demonstrate a good in vivo/in vitro correlation for the effects of coumarin and dihydrocoumarin in rat hepatocytes. Furthermore, the data suggest that coumarin hepatoxicity in the rat is due to coumarin bioactivation by cytochrome P450-dependent enzymes to a toxic metabolite(s), which may be a coumarin 3,4-epoxide intermediate. GSH appears to protect against coumarin-induced toxicity possibly by the formation of conjugates with the toxic coumarin metabolite(s).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2922762     DOI: 10.1016/0041-008x(89)90336-0

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  4 in total

1.  A comparison of US and Norwegian regulation of coumarin in tobacco products.

Authors:  M Givel
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

2.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches.

Authors:  Yen Low; Takeki Uehara; Yohsuke Minowa; Hiroshi Yamada; Yasuo Ohno; Tetsuro Urushidani; Alexander Sedykh; Eugene Muratov; Viktor Kuz'min; Denis Fourches; Hao Zhu; Ivan Rusyn; Alexander Tropsha
Journal:  Chem Res Toxicol       Date:  2011-07-21       Impact factor: 3.739

3.  A kinetic study of the main guaco metabolites using syrup formulation and the identification of an alternative route of coumarin metabolism in humans.

Authors:  João Cleverson Gasparetto; Rosângela Gonçalves Peccinini; Thais Martins Guimarães de Francisco; Letícia Bonâncio Cerqueira; Francinete Ramos Campos; Roberto Pontarolo
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

4.  The Relation between Hepatotoxicity and the Total Coumarin Intake from Traditional Japanese Medicines Containing Cinnamon Bark.

Authors:  Naohiro Iwata; Mosaburo Kainuma; Daisuke Kobayashi; Toshio Kubota; Naoko Sugawara; Aiko Uchida; Sahoko Ozono; Yuki Yamamuro; Norihiro Furusyo; Koso Ueda; Eiichi Tahara; Takao Shimazoe
Journal:  Front Pharmacol       Date:  2016-06-20       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.